Conveniently dosed at 600 mg twice
daily, it can be administered intravenously
or orally in a 1:1 ratio
Notable warnings
and precautions are serotonin syndrome,
myelosuppression, and postmarketing
reports of hypoglycemia with concomitant
use of antihyperglycemic agents
Since its release, however, there have
been reports of MRSA strains resistant to
linezolid due to the acquisition of a natural
resistance gene known as (chloramphenicol-
fl orfenicol resistance). As a result, Cfr
methyltransferase is expressed and alters
the 23S rRNA component of the ribosomal
subunit in bacteria.7,8 Introducing a unique
challenge for the management of multidrugresistant
gram-positive organisms, new
drug developments have been explored.
In June 2014, the FDA approved tedizolid
phosphate (Sivextro, Cubist Pharmaceuticals)
as a second-generation oxazolidinone
with potentially four- to 16-fold
potency against MRSA when compared with
linezolid.9–11 Favorable results from clinical
trials have led to its indication for the
treatment of ABSSSIs in adult patients with
susceptible bacteria.11 This article reviews
the information available to date on this
product in relation to safety and efficacy